Heart FailureHFrecEFNCT06724653
Tapering Heart Failure Medication in Patients With Heart Failure With Recovered Ejection Fraction; Open Label Prospective Random Trial
A study testing RAS blocker tapering group and Beta blocker tapering out in people with Heart Failure and Ejection Fraction, run by Chungnam National University Hospital at 2 sites in South Korea.
Trial summary
Study start date is on Nov 27th 2024. A patient with an initial ejection fraction (EF) of less than 40%, whose follow-up shows an improvement to an EF of 50% or higher, along with the left ventricular end-diastolic diameter returning to the normal range and taking 3 more heart failure medication randomed to drug… Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Heart Failure, Ejection Fraction, Recovery of Function
- What is being tested?
- RAS blocker tapering group and Beta blocker tapering out
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 150 participants
- Where
- 2 sitesSouth Korea
- Study dates
- 6 Mar 2025to 26 Nov 2027
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- initial echocardiogram ejection fraction less than 40%
- follow up echocardiogram ejection fraction over 50% and LVEDD index normal range
- NTprobnp criteria
- eGFR ≥60 ; less 440
- eGFR 45-59: less 980
- eGFR 30-44; less 1220
Show all 9Show fewer
- eGFR < 30 : less 5300
- in HD; no criteria for NTproBNP
- on more than 3 heart failure medication ( RAS blocker, beta blocker, mineral corticoid receptor antagonist, SGLT 2 inhibitor)
Who cannot join
- under age 18 year
- uncontrolled BP ( over 150/90)
- coronary revascularization within 6 months
- significant valve disease
- arrhythmia requiring rate control
- CKD with albuminuria ( over 30mg/g)
- Pregnancy
Trial locations and contacts
2 sites in 1 country. Contact the study team or a site near you to ask about taking part.
South Korea2 sites, 2 recruiting
- Recruiting
Chungnam national university hospital
Daejeon, Republic of Korea, 35015
Yujin Yang, 01043311245, wjsdudtns9@gmail.com
- Recruiting
Jeonbuk national university hospital
Jeonju, Jeollabuk-do, 54907
Jiyeonn Lee, 82-10-5589-0144, yony07777@naver.com
About this study
Study start date is on Nov 27th 2024.
A patient with an initial ejection fraction (EF) of less than 40%, whose follow-up shows an improvement to an EF of 50% or higher, along with the left ventricular end-diastolic diameter returning to the normal range and taking 3 more heart failure medication randomed to drug tapering group ( RAS blocker or beta blocker) or continuing medication group.
Read the detailed description
Patients described above randomly assigned to drug tapering group and drug maintaining group.
Drug tapering group is 2 groups, which one is RAS blocker tapering group and others is beta blocker tapering group.
Drug tapering group is monitored ejection fraction, LV dimension and LV GLS by 1-3 month.
- Conditions
- Heart Failure, Ejection Fraction, Recovery of Function
- Being tested
- RAS blocker tapering group, Beta blocker tapering out
- Keywords
- heart failure with recovered ejection fraction, Tapering
- Medical subject headings
- Heart Failure
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
RAS blocker tapering groupDrug
RAS blocker tapering out
Beta blocker tapering outDrug
Beta blocker tapering out group
| Study group | Role | What they receive |
|---|---|---|
| RAS blocker tapering arm | Active comparator | RAS blocker tapering Receives: Drug: RAS blocker tapering group; Drug: Beta blocker tapering out |
| Beta blocker tapering arm | Active comparator | Beta blocker tapering arm |
| Control | Placebo comparator | Drug maintain group |
What is being measured
The primary outcome is the main question the study is designed to answer.
Heart failure relapse
LVEF 10% drop, EF less than 50 %, LVIDd/BSA 10% increase, over 33mm/m^2
Measured: From enrollment to the end of treatment at 18 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted9 Dec 2024
- Study start6 Mar 2025
- Primary completion26 May 2025
- Study completion26 Nov 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Heart FailureStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- randomly assignment to 3 groups ( drug tapering\_RAS blocker, beta blocker, drug maintaining)
- Masking
- Single blind
- Who is masked
- Outcomes assessor
- Enrolment
- 150 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Chungnam National University Hospital
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06724653
- Sponsor's protocol ID
- IRB 2024-09-039-002
- Other IDs
- 2024-09-039-002
- Acronym
- HFrecEF
- Status last verified
- Mar 2026
- First submitted
- 5 Dec 2024
- Last updated
- 27 Mar 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Yes
Study at a glance
From the registry record, last updated by the sponsor on 27 Mar 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Tapering Heart Failure Medication in Patients With Heart Failure With Recovered Ejection Fraction; Open Label Prospective Random Trial
- ClinicalTrials.gov ID
- NCT06724653
- Acronym / sponsor ID
- HFrecEF / IRB 2024-09-039-002
- Conditions
- Heart Failure, Ejection Fraction, Recovery of Function
- Keywords
- heart failure with recovered ejection fraction, Tapering
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 150 participants (estimated)
- Lead sponsor
- Chungnam National University HospitalUniversity, hospital or other
- Study start
- 6 Mar 2025 (actual)
- Primary completion
- 26 May 2025 (actual)
- Study completion
- 26 Nov 2027 (estimated)
- First posted
- 9 Dec 2024 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Study start date is on Nov 27th 2024.
A patient with an initial ejection fraction (EF) of less than 40%, whose follow-up shows an improvement to an EF of 50% or higher, along with the left ventricular end-diastolic diameter returning to the normal range and taking 3 more heart failure medication randomed to drug tapering group ( RAS blocker or beta blocker) or continuing medication group.
Detailed description
Patients described above randomly assigned to drug tapering group and drug maintaining group.
Drug tapering group is 2 groups, which one is RAS blocker tapering group and others is beta blocker tapering group.
Drug tapering group is monitored ejection fraction, LV dimension and LV GLS by 1-3 month.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind (outcomes assessor)
- Number of arms
- 3
- Model description
- randomly assignment to 3 groups ( drug tapering_RAS blocker, beta blocker, drug maintaining)
| Arm | Type | Receives |
|---|---|---|
| RAS blocker tapering arm | Active comparator | Drug: RAS blocker tapering group, Drug: Beta blocker tapering outRAS blocker tapering |
| Beta blocker tapering arm | Active comparator | –Beta blocker tapering arm |
| Control | Placebo comparator | –Drug maintain group |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (9 listed)
- initial echocardiogram ejection fraction less than 40%
- follow up echocardiogram ejection fraction over 50% and LVEDD index normal range
- NTprobnp criteria
- on more than 3 heart failure medication ( RAS blocker, beta blocker, mineral corticoid receptor antagonist, SGLT 2 inhibitor)
Key exclusion criteria (7 listed)
- under age 18 year
- uncontrolled BP ( over 150/90)
- coronary revascularization within 6 months
- significant valve disease
- arrhythmia requiring rate control
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| RAS blocker tapering groupRAS blocker tapering out | Drug | RAS blocker tapering arm |
| Beta blocker tapering outBeta blocker tapering out group | Drug | RAS blocker tapering arm |
Primary outcome
Heart failure relapse
Time frame: From enrollment to the end of treatment at 18 months
LVEF 10% drop, EF less than 50 %, LVIDd/BSA 10% increase, over 33mm/m^2
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 27 Mar 2026.
- Individual participant dataSharing planned: Yes
Related trials for Heart Failure
RecruitingPhase 4
The Effects of Ferric Derisomaltose in Patients With Acute Heart Failure and Iron Deficiency on Exercise Capacity and Quality of Life(COREVIVE-HFrEF)
Heart Failure With Reduced Ejection Fraction, Iron Deficiency
Not yet recruitingPhase 2
A Study of Bimagrumab in Participants With HFpEF
Heart Failure, Diastolic, Diastolic Heart Failure
Recruiting
Evaluation of a French Hospital Discharge Therapeutic Education Program by Nurses for Heart Failure Patient (EduSor)
Heart Failure
Active, not recruiting
Assessment of Combined CCM and ICD Device in HFrEF
Heart Failure, Heart Failure With Reduced Ejection Fraction
Not yet recruiting
RELIEVE-HFrEF TRIAL: REducing Lung congestIon Symptoms Using the v-wavE Shunt in adVancEd Heart Failure With Reduced EF
Heart Failure and Reduced Ejection Fraction, Heart Failure Chronic
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
2 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing RAS blocker tapering group and Beta blocker tapering out in people with Heart Failure and Ejection Fraction, run by Chungnam National University Hospital at 2 sites in South Korea.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 9 inclusion and 7 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 27 Mar 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 2 sites in South Korea. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Yujin Yang (821043311245, wjsdudtns9@gmail.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Heart failure relapse (time frame: From enrollment to the end of treatment at 18 months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 27 Mar 2026.